Products
Melrilimab Biosimilar Monoclonal Antibody (ST2) for Research
Pre-Made Melrilimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Melrilimab (formerly GSK 3772847) was a monoclonal antibody targeting interleukin-1 receptor-like 1 (IL1RL1 or ST2 or IL-33R), which was being developed by GlaxoSmithKline for the treatment of asthma and atopic dermatitis. Clinical development was ongoing in the US and the UK.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-340-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Melrilimab biosimilar, Whole mAb, Anti-IL1RL1/ST2 Antibody: Anti-DER4/FIT-1/IL33R/T1 therapeutic antibody |
| INN Name | Melrilimab |
| Target | IL1RL1 |
| Format | Whole mAb |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG2 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2020 |
| Year Recommended | 2021 |
| Companies | GlaxoSmithKline |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Asthma;Atopic dermatitis |
| Development Tech | na |
About target - IL1RL1
1. Protein Interleukin-1 receptor-like 1
2. Gene IL1RL1
3. Organism Homo sapiens (Human)
Function
Receptor for interleukin-33 (IL-33); signaling requires association of the coreceptor IL1RAP. Its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6, followed by phosphorylation of MAPK3/ERK1 and/or MAPK1/ERK2, MAPK14, and MAPK8. Possibly involved in helper T-cell function.
Isoform B:
Inhibits IL-33 signaling.
Catalytic activity
H2O + NAD+ = ADP-D-ribose + H+ + nicotinamide
EC:3.2.2.6
This reaction proceeds in the forward
